Floatz logo

Recombinant Fowlpox-Cea/Tricom Vaccine

Recurrent Gastric Cancer

National Cancer Institute (NCI)vaccinePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
29/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Recurrent Gastric Cancer cohort.

Asset / SponsorPhaseRating
Recombinant Interleukin-12
National Cancer Institute (NCI)
Phase 1CCC
ANTI-HER2 ANTIBODY-DRUG CONJUGATE A166
Klus Pharma Inc.
Phase 1/2CCC
Modified Vaccinia Virus Ankara Vaccine Expressing P53
City of Hope Medical Center
Phase 1CC
7-hydroxystaurosporine
National Cancer Institute (NCI)
Phase 1CC
Recombinant Fowlpox-Gm-Csf
National Cancer Institute (NCI)
Phase 1CC

View all 13 →

Same molecule, other indications

Recombinant Fowlpox-Cea/Tricom Vaccine is also rated in:

Breast CancerDormant
CC
Indicative ·
47 / 100
View asset →
Metastases, NeoplasmDormant
CC
Indicative ·
45 / 100
View asset →
Recurrent Colon CancerDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →